Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 501 to 550 of 797

TitleReference numberPublishedLast updated
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Naltrexone–bupropion for managing overweight and obesityTA494
Vismodegib for treating basal cell carcinomaTA489
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumoursTA488
Sarilumab for moderate to severe rheumatoid arthritisTA485
Aflibercept for treating choroidal neovascularisationTA486
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Immunosuppressive therapy for kidney transplant in adultsTA481
Immunosuppressive therapy for kidney transplant in children and young peopleTA482
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the kneeTA477
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphomaTA478
Reslizumab for treating severe eosinophilic asthmaTA479
Cetuximab and panitumumab for previously untreated metastatic colorectal cancerTA439
Pembrolizumab for advanced melanoma not previously treated with ipilimumabTA366
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357
Sorafenib for treating advanced hepatocellular carcinomaTA474
Dimethyl fumarate for treating moderate to severe plaque psoriasisTA475
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancerTA476
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neckTA473
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)TA468
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)TA469
Holoclar for treating limbal stem cell deficiency after eye burnsTA467
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190
Cabozantinib for previously treated advanced renal cell carcinomaTA463
Baricitinib for moderate to severe rheumatoid arthritisTA466
Adalimumab and dexamethasone for treating non-infectious uveitisTA460
Roflumilast for treating chronic obstructive pulmonary diseaseTA461
Nivolumab for treating relapsed or refractory classical Hodgkin lymphomaTA462
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopleTA455
Ustekinumab for moderately to severely active Crohn's disease after previous treatmentTA456
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)TA452
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)TA453
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA454
Etelcalcetide for treating secondary hyperparathyroidismTA448
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive diseaseTA449
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemiaTA450
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemiaTA451
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDsTA445
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabineTA440
Ixekizumab for treating moderate to severe plaque psoriasisTA442
Obeticholic acid for treating primary biliary cholangitisTA443
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)TA240
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)TA437
Elotuzumab for previously treated multiple myeloma (terminated appraisal)TA434
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)TA435

Results per page

  1. 10
  2. 25
  3. 50
  4. All